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Hepatocyte-secreted DPP4 in obesity promotes 
adipose inflammation and insulin resistance
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Obesity-induced metabolic disease involves functional integration 
among several organs via circulating factors, but little is known 
about crosstalk between liver and visceral adipose tissue (VAT)1. In 
obesity, VAT becomes populated with inflammatory adipose tissue 
macrophages (ATMs)2,3. In obese humans, there is a close correlation 
between adipose tissue inflammation and insulin resistance4,5, and 
in obese mice, blocking systemic or ATM inflammation improves 
insulin sensitivity6–8. However, processes that promote pathological 
adipose tissue inflammation in obesity are incompletely understood. 
Here we show that obesity in mice stimulates hepatocytes to 
synthesize and secrete dipeptidyl peptidase 4 (DPP4), which acts 
with plasma factor Xa to inflame ATMs. Silencing expression of 
DPP4 in hepatocytes suppresses inflammation of VAT and insulin 
resistance; however, a similar effect is not seen with the orally 
administered DPP4 inhibitor sitagliptin. Inflammation and insulin 
resistance are also suppressed by silencing expression of caveolin-1 
or PAR2 in ATMs; these proteins mediate the actions of DPP4 and 
factor Xa, respectively. Thus, hepatocyte DPP4 promotes VAT 
inflammation and insulin resistance in obesity, and targeting this 
pathway may have metabolic benefits that are distinct from those 
observed with oral DPP4 inhibitors.
In obese mice and humans, a pathway in hepatocytes involving 
Ca2+–calmodulin-dependent protein kinase II (CaMKII) contributes to 
both excessive hepatic glucose production and impaired hepatic insulin 
signalling9–11. Inhibition of this pathway by hepatocyte-specific dele-
tion of CaMKIIγ in diet-induced obese (DIO) mice (Camk2gfl/fl mice 
infected with AAV8-TBG-cre, hereafter referred to as H-CaMKII(KO) 
mice, improves glucose and insulin tolerance9,10. Notably, the VAT 
of these mice had fewer ATMs in crown-like structures (CLS) and 
decreased Adgre1 mRNA (which encodes the F4/80 glycoprotein) in 
comparison to VAT of control Camk2gfl/fl DIO mice (Extended Data 
Fig. 1a). There was also decreased infiltration of inflammatory Ly6Chi 
monocytes and lower inflammatory cytokine expression in the VAT 
of H-CaMKII(KO) mice, with no significant change in blood mono-
cyte number, plasma IL6 or TNFα, or liver inflammation (Extended 
Data Fig. 1b–e). ATF4 expression is regulated downstream of CaMKII 
signalling and is decreased in the hepatocytes of H-CaMKII(KO) DIO 
mice10. Restoring ATF4 expression in the livers of mice deficient in 
hepatocyte CaMKII using an adenovirus vector restored VAT inflam-
mation without affecting liver inflammation (Extended Data Fig. 1f, g). 
Conversely, hepatocyte-specific deletion of ATF4 in DIO mice lowered 
VAT inflammation (Extended Data Fig. 1h). Therefore, we hypothe-
sized that, in obesity, activation of CaMKII and ATF4 in hepatocytes 
induces the secretion of a circulatory factor (a ‘hepatokine’) that pro-
motes VAT inflammation.
To test this hypothesis, we developed an ex vivo assay in which cells 
from the stromal vascular fraction (SVF) of VAT are incubated with 
plasma from the above mouse models, and Mcp1 (also known as Ccl2) 
and Il6 mRNA are quantified as markers of inflammation. Because 
VAT macrophages are a likely target of the putative hepatokine, we 
predicted that cells from the SVF of VAT from obese mice, which har-
bour more of these macrophages4,5 (Extended Data Fig. 2a), would 
show an increased response in this assay in comparison to SVF cells 
from lean mice. Plasma from obese mice would also be expected to 
evoke a more potent response in the assay than plasma from lean mice. 
Consistent with this hypothesis, plasma from DIO mice induced higher 
expression of both Mcp1 and Il6 mRNA than plasma from lean mice 
in SVF cells from DIO mice, but did not have this effect on SVF cells 
from lean mice. Furthermore, the inflammatory activity of plasma 
from DIO mice was due to the macrophage component of SVF cells 
(Fig. 1a and Extended Data Fig. 2b). DIO mouse plasma was also able 
to induce Mcp1 expression in peritoneal and bone marrow-derived 
macrophages (BMDMs; Extended Data Fig. 2c). Most importantly, 
plasma from H-CaMKII-(KO) DIO mice was less able to induce Mcp1 
expression in SVF than plasma from either wild-type DIO mice or 
H-CaMKII(KO) mice in which hepatic ATF4 expression was restored 
(Fig. 1b). These data suggest that, in obesity, activation of hepatocyte 
CaMKII and ATF4 induce one or more secretory factors that promote 
VAT-macrophage inflammation.
The Mcp1-inducing factor in DIO mouse plasma was heat labile 
(Extended Data Fig. 2d), suggesting that it may be a protein. We per-
formed size-exclusion gel-filtration fast protein liquid chromatography 
(FPLC) with DIO mouse plasma (Extended Data Fig. 2e) and tested 
eluted fractions for their ability to induce Mcp1 expression in SVF cells. 
There was a peak of activity in three fractions in the 125–200 kDa range 
(Extended Data Fig. 2f). The active fraction F44 and inactive fractions 
F42 and F46 were analysed by liquid chromatography–tandem mass 
spectrometry (LC–MS/MS) to identify peptides that were more abun-
dant in F44 than in F42 and F46 (Supplementary Table 2a). Peptides 
corresponding to DPP4 (CD26) met these criteria (Extended Data 
Fig. 2g). DPP4 is a dipeptidyl protease that can exist as either a cell 
membrane protein or a soluble plasma protein12. DPP4 concentration 
correlates with body mass index and insulin resistance in humans13,14, 
and we found that DPP4 activity was higher in the plasma of DIO mice 
than in that of lean mice (Extended Data Fig. 2h).
Consistent with a role for DPP4, the Mcp1- and Il6-inducing activity 
of DIO mouse plasma could be suppressed by an inhibitor of DPP4 
(Fig. 1c and Extended Data Fig. 2i). Furthermore, DPP4 activity in 
plasma and Dpp4 mRNA expression in liver, but not in VAT, correlated 
exactly with VAT inflammation in vivo and plasma SVF-inflammatory 
activity ex vivo in wild-type and H-CaMKII(KO) mice as well as in 
H-CaMKII(KO) mice in which hepatic ATF4 expression was restored 
(Fig. 1d and Extended Data Fig. 2j). Moreover, restoration of hepatic 
DPP4 expression in H-CaMKII(KO) mice restored DPP4 activity 
in plasma and VAT inflammation without changing body weight 
(Extended Data Fig. 3a, b). Consistent with the role of ATF4, we 
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found an ATF4-consensus site in exon 1 of the Dpp4 gene. Chromatin 
immuno precipitation (ChIP) analysis revealed lower levels of ATF4 
occupancy at this site in the livers of H-CaMKII(KO) DIO mice versus 
those of wild-type DIO or H-CaMKII(KO) DIO mice in which hepato-
cyte ATF4 expression was restored (Extended Data Fig. 3c).
We infected DIO mice with an adeno-associated virus 8 (AAV8) that 
encoded a short hairpin RNA (shRNA) construct targeting mouse Dpp4 
driven by the H1 promoter. AAV8-H1-shDpp4 specifically silences 
DPP4 in hepato cytes but not in VAT or other tissues (Extended Data 
Fig. 3d, e); we refer to the vector as H-shDpp4 to reflect its hepatocyte 
specificity. H-shDpp4-treated DIO mice had significantly decreased 
plasma DPP4 activity (Fig. 1e), indicating that hepatocytes are a source 
of circulating DPP4 in obesity. H-shDpp4-treated DIO mice also had 
decreased numbers of CLS macrophages in the VAT and decreased 
levels of inflammatory cytokine mRNAs in VAT and VAT ATMs (Fig. 
1f and Extended Data Fig. 4a, b). However, these mice did not differ 
from control vector-treated DIO mice with regard to inflammation in 
inguinal or brown fat, plasma cytokines, body weight, food intake or 
liver or adipose tissue weight (Extended Data Fig. 4c–g). H-shDpp4-
treated DIO mice also exhibited improved glucose homeostasis and 
increased insulin-induced AKT phosphorylation (p-AKT) in VAT and 
liver (Fig. 1g and Extended Data Fig. 4h, i). Unlike DPP4 inhibition15, 
silencing of hepatocyte DPP4 did not increase levels of active plasma 
incretins (Extended Data Fig. 4j). Similar data were obtained when 
ob/ob mice were treated with the H-shDpp4 (Extended Data Fig. 5a–h). 
By contrast, treatment of lean mice with the H-shDpp4 had no effect 
on metabolism (Extended Data Fig. 5i–m), and DPP4 silencing did 
not improve insulin signalling in palmitate-treated primary hepato-
cytes (Extended Data Fig. 6a). Moreover, consistent with the idea that 
adipocyte-derived non-esterified fatty acids (NEFA) may contribute 
to inflammation-induced insulin resistance16, H-shDpp4 treatment 
lowered plasma NEFA in obese but not in lean mice (Extended Data 
Fig. 6b). These combined data suggest that the improvement in meta-
bolism in DIO mice treated with H-shDpp4 is caused by suppression of 
VAT inflammation, which improves insulin signalling in hepatocytes 
and VAT as a secondary effect rather than via a direct effect on insulin 
signalling in hepatocytes.
Oral DPP4 inhibitors do not lower plasma insulin in insulin-resistant, 
hyperinsulinaemic subjects17–22. A recent study suggested that in obese 
mice, oral DPP4 inhibitors function by inhibiting gut endothelial 
DPP423. We tested the hypothesis that oral DPP4 inhibition and hepato-















































































































































































































































































Figure 1 | Hepatocyte-specific DPP4 silencing suppresses VAT 
inflammation and improves insulin sensitivity in DIO mice. a, VAT SVF 
cells from DIO mice, and ATMs and non-ATMs isolated from SVF, were 
incubated for 4 h with medium containing 10% (vol/vol) plasma from lean 
or DIO mice and then assayed for Mcp1 or Il6 mRNA (n = 4–6 mice per 
group; *P < 0.05 by two-tailed Student’s t-test). b, VAT SVF cells from DIO 
mice were incubated with plasma from the three DIO models described 
in Extended Data Fig. 1f, g and then assayed for Mcp1 mRNA. WT, wild 
type. n = 8 mice per group; mean ± s.e.m.; *P < 0.05 by one-way analysis 
of variance (ANOVA). c, SVF cells from DIO mice were incubated with 
lean or DIO mouse plasma that was pre-treated for 1 h with or without 
10 μM DPP4 inhibitor KR62436 and then assayed for Mcp1 mRNA (n = 3 
technical replicates; mean ± s.e.m.; *P < 0.05 by one-way ANOVA). d, 
The three groups of mice from Extended Data Fig. 1f, g were assayed for 
plasma DPP4 activity and hepatic Dpp4 mRNA (n = 4 mice per group; 
mean ± s.e.m.; *P < 0.05 by one-way ANOVA). e–g, Sixteen-week-old 
mice previously fed the DIO diet for 10 weeks were injected intravenously 
with AAV8-H1-shDpp4 (H-shDpp4) or control AAV8-H1 vector 
(control; or con, in f). The mice were analysed after four weeks as follows. 
e, Plasma DPP4 activity. f, CLS macrophages and Adgre1 mRNA in VAT, 
with representative images of F4/80-stained VAT. g, Blood glucose after 
intraperitoneal glucose or insulin (n = 6 mice per group; mean ± s.e.m.; 
*P < 0.05 by two-tailed Student’s t-test).
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inflammation and glucose metabolism: we directly compared treatment 
with the oral DPP4 inhibitor sitagliptin with silencing of hepatocyte 
DPP4 in DIO mice. After four weeks, neither treatment affected body 
weight; both treatments lowered plasma DPP4 activity to a similar 
degree and neither treatment affected DPP4 activity in VAT (Extended 
Data Fig. 6c, d). However, H-shDpp4, but not sitagliptin, decreased 
hepatic DPP4 protein and hepatocyte DPP4 activity (Extended Data 
Fig. 6e). Conversely, sitagliptin, but not H-shDpp4, increased plasma 
incretins (Fig. 2a), consistent with our shDpp4 data and the known 
action of oral DPP4 inhibitors. Notably, H-shDpp4, but not sitagliptin, 
suppressed VAT inflammation (Fig. 2b, c), and although both treat-
ments lowered blood glucose and improved oral glucose tolerance, 
only H-shDpp4 lowered plasma insulin, improved glucose response 
to intraperitoneal glucose and insulin, showed evidence of increased 
insulin-induced p-AKT in VAT and liver and lowered plasma NEFA 
(Fig. 2d and Extended Data Fig. 6f–h). Consistent with these results, 
both sitagliptin and H-shDpp4 treatments lowered plasma DPP4 activ-
ity and blood glucose, but only H-shDpp4 decreased plasma insulin 
levels after 11 weeks, without a change in body weight (Extended Data 
Fig. 6i). Thus, DPP4 inhibition by orally administered sitagliptin and 
hepatocyte DPP4 silencing have fundamentally different effects on VAT 
inflammation and metabolism.
Next, we investigated the mechanism of DPP4-induced VAT macro-
phage inflammation. Although recombinant DPP4 (rDPP4) alone 
was unable to induce Mcp1 or Il6 expression in SVF, it did so when 
added to either DIO mouse plasma that had been immunodepleted of 
DPP4 or plasma from DIO mice that had been treated with H-shDpp4 
(Extended Data Fig. 7a, b). To determine whether an additional plasma 
factor was needed for DPP4 to promote SVF inflammation, plasma 
from DIO mice was immunodepleted of DPP4 and then fractionated 
using FPLC. Two fractions (F43 and F44) were able to induce Mcp1 in 
SVF cells in the presence of rDPP4, but not in its absence (Extended 
Data Fig. 7c). Fraction F44 and the inactive fractions F42 and F46 were 
then analysed by LC–MS/MS to identify peptides that were more abun-
dant in F44 versus F42 and F46 (Supplementary Table 2b). Peptides cor-
responding to plasma factor X met these criteria (Extended Data Fig. 
8a). Factor X can trigger inflammation in endothelial cells and leuko-
cytes24,25, and we found that the ability of DIO plasma to induce Mcp1 
expression in SVF cells or macrophages was abrogated by rivaroxaban, 
an inhibitor of factor Xa (FXa) (Extended Data Fig. 8b). Furthermore, 
whereas recombinant factor X (rFX) or rDPP4 alone led to only very 
small increases in Mcp1 and Il6 expression in macrophages, combined 
treatment with both rFX and rDPP4 was much more potent, and this 
inflammatory activity was inhibited by either rivaroxaban or a DPP4 
inhibitor (Fig. 3a and Extended Data Fig. 8c). These data also imply 
that factor X is converted to FXa by macrophages26. Using recombinant 
FXa (rFXa) directly, we showed that rFXa and rDPP4 together were able 
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Figure 2 | Silencing of hepatocyte DPP4, but not treatment with the  
oral DPP4 inhibitor sitagliptin, lowers VAT inflammation and 
improves metabolism in DIO mice. a–d, Control, H-shDpp4- and 
sitagliptin-treated mice from those described in Extended Data Fig. 6c–h  
were analysed as follows. a, Plasma active GIP (1–42) and GLP1 (7–36). 
NS, not significant. b, CLS macrophages and Adgre1 mRNA in VAT, 
with representative images of F4/80-stained VAT. c, Il6, Mcp1, Tnfa 
and Il1b mRNA in VAT. d, Blood glucose after oral glucose (O-GTT), 
intraperitoneal glucose (IP-GTT), or intraperitoneal insulin (IP-ITT). 
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Figure 3 | DPP4 and FXa synergistically activate inflammatory 
signalling in macrophages. a, BMDMs were pretreated with or without 
10 μM FXa inhibitor rivaroxaban or 10 μM DPP4 inhibitor KR62436, 
followed by incubation for 4 h with rFX or rDPP4 alone or in combination. 
Mcp1 mRNA was then quantified. n = 4 technical replicates per group; 
mean ± s.e.m.; *P < 0.05 by one-way ANOVA. b, c, Sixteen-week-old 
mice previously fed the DIO diet for 10 weeks were treated for 20 days 
with 2 mg kg−1 oral rivaroxaban twice daily (Riv) or vehicle control and 
analysed as follows. b, CLS macrophages and Adgre1 mRNA in VAT, 
with representative images of F4/80-stained VAT. c, Blood glucose after 
intraperitoneal glucose or insulin (n = 5 mice per group; mean ± s.e.m.; 
*P < 0.05 by two-tailed Student’s t-test). d, e, BMDMs from wild-type, 
CAV1 knockout (CAV1 KO) or PAR2 knockout (PAR2 KO) mice were 
incubated for 4 h with or without rFXa and rDPP4 and then assayed for 
Mcp1 and Il6 mRNA. n = 4 technical replicates per group; mean ± s.e.m.; 
*P < 0.05 by two-way ANOVA.
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lean mouse SVF cells (Extended Data Fig. 8d). Treatment of DIO mice 
with rivaroxaban lowered VAT inflammation and plasma NEFA, and 
improved metabolism, without affecting body weight (Fig. 3b, c and 
Extended Data Fig. 8e–j).
To understand how the combination of DPP4 and FXa induces 
Mcp1 expression, we pre-treated macrophages with rFXa and then, 
after removing the rFXa and inhibiting residual activity with rivar-
oxaban, treated the cells with rDPP4. We also conducted the reverse 
experiment by pre-treating the cells with rDPP4 and then, after remov-
ing the rDPP4 and inhibiting residual activity with a DPP4 inhibitor, 
treated the cells with rFXa. Both protocols increased Mcp1 and Il6 
mRNA expression (Extended Data Fig. 9a, b), suggesting that neither 
a complex between FXa and DPP4 nor a specifically ordered prim-
ing event is needed. We therefore hypothesized that each factor alone 
partially activates inflammatory signalling to a sub-threshold level, 
and that the threshold is reached only when both factors are present. 
Inflammation induced by rDPP4 and rFXa was markedly reduced 
in macrophages from mice lacking either caveolin-1 (CAV1), which 
mediates the inflammatory effects of DPP4 on antigen-presenting 
cells27, or PAR2, a cell-surface receptor that mediates the inflam-
matory effects of FXa in macrophages28 (Fig. 3d, e). Similar results 
were observed in VAT-derived ATMs from DIO mice, and human 
macrophages treated with inhibitors of CAV1 or PAR2 (Extended 
Data Fig. 9c, d). Consistent with the signalling-threshold hypothesis, 
rDPP4 alone increased phosphorylation of two reported CAV1 sig-
nalling intermediates, IRAK1 and TAK1 (Extended Data Fig. 9e), and 
rFXa alone increased phosphorylation of the PAR2 signalling inter-
mediate RAF1 (Extended Data Fig. 9f), but only combined treatment 
with rDPP4 and rFXa was able to activate two distal inflammatory 
signalling molecules, ERK1/2 and NF-κB (Extended Data Fig. 9g). 
Pharmacological inhibition of these signalling molecules abolished 
rDPP4–rFXa-induced Mcp1 and Il6 expression (Extended Data Fig. 
9c, h–j). Together, these data suggest that DPP4 and FXa activate two 
separate upstream pathways that synergistically stimulate ERK1/2 and 
NF-κB to induce Mcp1 and Il6 in ATMs.
Next, we determined whether inhibition of the above pathways in 
ATMs could ameliorate VAT inflammation and improve meta bolism 
in obese mice. Genes can be silenced specifically in ATMs in ob/ob 
mice by intraperitoneal administration of short interfering RNA 
(siRNA) encapsulated in micrometer-sized glucan shells, referred to 
as glucan-encapsulated siRNA particles (GERPs)8. Using this method, 
we determined the effect of decreasing Par2 and Cav1 expression in 
ATMs on VAT inflammation and glucose metabolism in ob/ob mice. 
In a pilot experiment using FITC-labelled glucan shells in ob/ob mice, 
we verified their increased localization to macrophages in VAT (ATMs) 
relative to macrophages in other organs (Extended Data Fig. 10a). 
We then treated ob/ob mice with GERPs containing scrambled RNA 
(control), or siRNA targeting PAR2 or CAV1, over a 12-day period. 
Body weight was similar in all three cohorts (Extended Data Fig. 10b). 
PAR2 and CAV1 levels were decreased by the respective GERPs in 
ATMs but not in spleen (Extended Data Fig. 10c). Notably, both GERPs 
lowered VAT inflammation, improved glucose intolerance, increased 
insulin-induced p-AKT in VAT and liver and decreased plasma NEFA 
(Fig. 4a–d and Extended Data Fig. 10d, e).
These findings emphasize the important role of crosstalk between 
hepatocytes and adipose tissue in metabolic disease (Fig. 4e) and the 
distinct effects of silencing hepatocyte DPP4 expression versus DPP4 
inhibition by oral inhibitors, which are widely used to treat type 2 dia-
betes. Although sitagliptin has been reported to lower adipose inflam-
mation in obese mice29, the drug was administered to young mice when 
they started receiving a high-fat diet, leading to an approximately 25% 
decrease in body weight in comparison to untreated mice. In our study, 
the drug was given to adult mice after obesity and VAT inflammation 
had developed, and it had no effect on body weight. We speculate that 
inhibition of circulating DPP4 activity does not block VAT inflam-
mation in adult obese mice because some other action of oral DPP4 
inhibition in that setting, perhaps related to the increase in plasma 
insulin30, counteracts the anti-inflammatory effect of lowering plasma 
DPP4 activity. While future work is needed to understand the role of 
the hepatocyte DPP4–FXa pathway in obese, insulin-resistant humans, 
we have preliminary data that shows that a high percentage of obese 
subjects with fat inflammation and a high homeostasis model assess-
ment (HOMA) index have inflammatory activity in their plasma that is 
dependent on DPP4, FXa and PAR2, whereas plasma from obese sub-
jects without fat inflammation and insulin resistance do not show this 
dependency. In conclusion, the identification of this pathway provides 
insight into how organ crosstalk can exacerbate metabolic disarray in 
obesity and raises the possibility that therapeutic silencing of hepato-
cyte DPP4— via hepatocyte-targeted siRNA31, for example—may have 
benefits for obesity-induced insulin resistance that are not achievable 
through currently available oral DPP4 inhibitors.
Online Content Methods, along with any additional Extended Data display items and 
Source Data, are available in the online version of the paper; references unique to 
these sections appear only in the online paper.
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Figure 4 | Silencing PAR2 or CAV1 in ATMs in obese mice lowers VAT 
inflammation and improves response to insulin. a–d, Five-week-old, 
chow-fed ob/ob mice were injected intraperitoneally once a day for 12 
days with 0.2 mg GERPs containing scrambled siRNA (control), Par2 
siRNA (siPar2) or Cav1 siRNA (siCav1). Twenty-four hours after the last 
injection, the mice were analysed as follows. a, CLS macrophages and 
Adgre1 mRNA in VAT, with representative images of F4/80-stained VAT. 
b, Blood glucose and plasma insulin 5 h after food withdrawal. c, Blood 
glucose after intraperitoneal glucose or insulin. d, Total AKT and p-AKT 
in VAT and liver after portal vein insulin injection. n = 5–6 mice per 
group; *P < 0.05 by two-tailed Student’s t-test for each siRNA GERP versus 
control GERP. For gel source data, see Supplementary Fig. 1. e, Summary 
scheme: obesity triggers a Ca2+–CaMKII–ATF4 pathway in hepatocytes, 
leading to induction of DPP4 and secretion of soluble DPP4 (sol-DPP4). 
Soluble DPP4 activates a CAV1–IRAK1–TAK1 pathway in ATMs, which, 
in combination with PAR2–RAF1 activation by FXa in ATMs, promotes 
ERK1/2–NF-kB-mediated inflammation. VAT inflammation exacerbates 
glucose intolerance, impaired insulin signalling in adipose and liver and 
hyperinsulinaemia.
© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
2 9  m a r c h  2 0 1 8  |  V O L  5 5 5  |  N a T U r E  |  6 7 7
Letter reSeArCH
1. Dasgupta, S. et al. NF-κB mediates lipid-induced fetuin-A expression in 
hepatocytes that impairs adipocyte function effecting insulin resistance. 
Biochem. J. 429, 451–462 (2010).
2. Weisberg, S. P. et al. Obesity is associated with macrophage accumulation in 
adipose tissue. J. Clin. Invest. 112, 1796–1808 (2003).
3. Xu, H. et al. Chronic inflammation in fat plays a crucial role in the 
development of obesity-related insulin resistance. J. Clin. Invest. 112, 
1821–1830 (2003).
4. Hardy, O. T. et al. Body mass index-independent inflammation in omental 
adipose tissue associated with insulin resistance in morbid obesity. Surg. Obes. 
Relat. Dis. 7, 60–67 (2011).
5. Blüher, M. Adipose tissue inflammation: a cause or consequence of 
obesity-related insulin resistance? Clin. Sci. (Lond.) 130, 1603–1614  
(2016).
6. Hotamisligil, G. S., Shargill, N. S. & Spiegelman, B. M. Adipose expression of 
tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 
259, 87–91 (1993).
7. Lumeng, C. N. & Saltiel, A. R. Inflammatory links between obesity and 
metabolic disease. J. Clin. Invest. 121, 2111–2117 (2011).
8. Aouadi, M. et al. Gene silencing in adipose tissue macrophages regulates 
whole-body metabolism in obese mice. Proc. Natl Acad. Sci. USA 110, 
8278–8283 (2013).
9. Ozcan, L. et al. Calcium signaling through CaMKII regulates hepatic glucose 
production in fasting and obesity. Cell Metab. 15, 739–751 (2012).
10. Ozcan, L. et al. Activation of calcium/calmodulin-dependent protein kinase II in 
obesity mediates suppression of hepatic insulin signaling. Cell Metab. 18, 
803–815 (2013).
11. Ozcan, L. et al. Hepatocyte DACH1 is increased in obesity via nuclear exclusion 
of HDAC4 and promotes hepatic insulin resistance. Cell Reports 15, 
2214–2225 (2016).
12. Boonacker, E. & Van Noorden, C. J. The multifunctional or moonlighting protein 
CD26/DPPIV. Eur. J. Cell Biol. 82, 53–73 (2003).
13. Kirino, Y., Sei, M., Kawazoe, K., Minakuchi, K. & Sato, Y. Plasma dipeptidyl 
peptidase 4 activity correlates with body mass index and the plasma 
adiponectin concentration in healthy young people. Endocr. J. 59, 949–953 
(2012).
14. Lamers, D. et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking 
obesity to the metabolic syndrome. Diabetes 60, 1917–1925 (2011).
15. Drucker, D. J. & Nauck, M. A. The incretin system: glucagon-like peptide-1 
receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. 
Lancet 368, 1696–1705 (2006).
16. Guilherme, A., Virbasius, J. V., Puri, V. & Czech, M. P. Adipocyte dysfunctions 
linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell Biol. 
9, 367–377 (2008).
17. Ristic, S., Byiers, S., Foley, J. & Holmes, D. Improved glycaemic control with 
dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin 
(LAF237) dose response. Diabetes Obes. Metab. 7, 692–698 (2005).
18. Aschner, P. et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as 
monotherapy on glycemic control in patients with type 2 diabetes. Diabetes 
Care 29, 2632–2637 (2006).
19. Raz, I. et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor 
sitagliptin as monotherapy in patients with type 2 diabetes mellitus. 
Diabetologia 49, 2564–2571 (2006).
20. Kutoh, E. & Ukai, Y. Alogliptin as an initial therapy in patients with newly 
diagnosed, drug naïve type 2 diabetes: a randomized, control trial. Endocrine 
41, 435–441 (2012).
21. Kadowaki, T. & Kondo, K. Efficacy, safety and dose-response relationship of 
teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 
2 diabetes mellitus. Diabetes Obes. Metab. 15, 810–818 (2013).
Supplementary Information is available in the online version of the paper.
Acknowledgements We thank F. S. Katz for assistance with FPLC; R. Kaufman 
for adeno-ATF4; C. Adams and S. Bullard for Atf4fl/fl mice; and A. Ferrante, 
S. Ramakrishnan, J. Weitz and T. McGraw for discussions. E.C. was supported 
by NIH grant 5P30CA013696-42. I.T. was funded by grants from the NIH 
(HL087123 and HL075662) and by a grant from the Merck Investigator Studies 
Program. L.O. was funded by the NIH grant DK106045 and a grant from the 
Columbia University Diabetes Research Center (P30 DK063608). Y.S., S.M.N. 
and M.P.C. were funded by NIH grant DK103047. M.B. was funded by the 
Deutsche Forschungsgemeinschaft grant SFB1052.
Author Contributions D.S.G., L.O. and I.T. designed the study, analysed data  
and wrote the manuscript. D.S.G., L.O. and Z.Z. conducted the experiments. 
S.M.N., Y.S. and M.P.C. made the glucan-encapsulated siRNA particles (GERPs) 
and helped design these experiments and analyse the data. E.C. conducted 
the LC–MS/MS studies and assisted with data analysis. M.B. helped with 
interpretation of data.
Author Information Reprints and permissions information is available at  
www.nature.com/reprints. The authors declare no competing interests.  
Readers are welcome to comment on the online version of the paper. 
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional 
claims in published maps and institutional affiliations. Correspondence and 
requests for materials should be addressed to L.O. (lo2192@columbia.edu) or 
I.T. (iat1@columbia.edu).
reviewer Information Nature thanks P. Scherer and the other anonymous 
reviewer(s) for their contribution to the peer review of this work.
22. Jung, C. H. et al. A randomized, double-blind, placebo-controlled, phase II 
clinical trial to investigate the efficacy and safety of oral DA-1229 in patients 
with type 2 diabetes mellitus who have inadequate glycaemic control with diet 
and exercise. Diabetes Metab. Res. Rev. 31, 295–306 (2015).
23. Mulvihill, E. E. et al. Cellular sites and mechanisms linking reduction of 
dipeptidyl peptidase-4 activity to control of incretin hormone action and 
glucose homeostasis. Cell Metab. 25, 152–165 (2017).
24. Senden, N. H. et al. Factor Xa induces cytokine production and expression of 
adhesion molecules by human umbilical vein endothelial cells. J. Immunol. 
161, 4318–4324 (1998).
25. Busch, G. et al. Coagulation factor Xa stimulates interleukin-8 release in 
endothelial cells and mononuclear leukocytes: implications in acute 
myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 25, 461–466 (2005).
26. McGee, M. P., Wallin, R., Wheeler, F. B. & Rothberger, H. Initiation of the extrinsic 
pathway of coagulation by human and rabbit alveolar macrophages: a kinetic 
study. Blood 74, 1583–1590 (1989).
27. Ohnuma, K. et al. CD26 mediates dissociation of Tollip and IRAK-1 from 
caveolin-1 and induces upregulation of CD86 on antigen-presenting cells.  
Mol. Cell. Biol. 25, 7743–7757 (2005).
28. Zuo, P. et al. Factor Xa induces pro-inflammatory cytokine expression in RAW 
264.7 macrophages via protease-activated receptor-2 activation. Am. J. Transl. 
Res. 7, 2326–2334 (2015).
29. Dobrian, A. D. et al. Dipeptidyl peptidase IV inhibitor sitagliptin reduces local 
inflammation in adipose tissue and in pancreatic islets of obese mice.  
Am. J. Physiol. Endocrinol. Metab. 300, E410–E421 (2011).
30. Pedersen, D. J. et al. A major role of insulin in promoting obesity-associated 
adipose tissue inflammation. Mol. Metab. 4, 507–518 (2015).
31. Fitzgerald, K. et al. A highly durable RNAi therapeutic inhibitor of PCSK9. 
 N. Engl. J. Med. 376, 41–51 (2017).
© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
LetterreSeArCH
MethOdS
Reagents and antibodies. Recombinant mouse and human DPP4 (catalogue 
no. 954-SE and 9168-SE, respectively) and anti-DPP4 antibody (AF954) were 
from R&D Systems. The PAR2 inhibitor GB83 was from Axon Medchem (1622). 
Recombinant FX (233282) and FXa (233526), and the MEK inhibitor PD98059 
(513000) were from Millipore. The FXa inhibitor rivaroxaban (S3002) was from 
Selleckchem. IRAK1–4 inhibitor I (A3505) and sitagliptin phosphate mono hydrate 
(A4036) were from ApexBio. Tri reagent (T9424), sodium palmitate (P9767), 
collagenase (C2139), liberase (5401020001), insulin (I9278), the DPP4 inhibitor 
KR-62436 hydrate (K4264), the caveolin-1 inhibitor daidzein (D7802), PS-1145, 
IKK inhibitor (P6624), the TAK1 MAPKKK inhibitor 5Z-7-oxozeaenol (O9890), 
anti-phospho-Thr209-IRAK1 (SAB4504246), and anti-β-actin antibody (A3854) 
were from Sigma. Anti-phospho-S473-AKT (4060), anti-AKT (4691), anti- 
phospho-Thr202/Tyr204-ERK1/2 (8544), anti-ERK (9194), anti-phospho-S536-
NF-κB p65 (3033), anti-NF-κB p65 (8242), anti-phospho-S412-TAK1 (9339), 
anti-TAK1 (5206), anti-phospho-S338-cRAF1 (9427), anti-cRAF1 (53745) and 
anti-caveolin-1 (3267) antibodies were from Cell Signaling. Anti-PAR2 anti-
body (817201) was from Biolegend. The DIO high-fat diet (60% kcal from fat) 
(D12492) was from Research Diets. Adenoviral Atf4 (adeno-Atf4) was a gift from 
R. J. Kaufman (Sanford–Burnham Medical Research Institute), adenoviral Dpp4 
(adeno-Dpp4) was purchased from Vector Biolabs, and adeno-associated virus 
8 (AAV8) containing either hepatocyte-specific TBG-Cre recombinase (AAV8-
TBG-cre) or the control vector (AAV8-TBG-lacZ) were purchased from the 
Penn Vector Core. All adenoviruses were amplified by Viraquest. The AAV8-H1-
shRNA construct targeting murine DPP4 was made by annealing complementary 
oligonucleotides and then ligating them into the pAAV-RSV-GFPH1 vector, as 
described previously32. The resultant constructs were amplified by Salk Institute 
Gene Transfer, Targeting, and Therapeutics Core. siRNA sequences against 
murine Par2 were purchased from GE Dharmacon and siRNA sequences against 
mouse Cav1 were purchased from Integrated DNA Technologies.
Mouse experiments. Camk2gfl/fl mice were generated as previously described10 and 
crossed onto the C57BL6/J background. Atf4fl/fl mice were generated as previously 
described33. Male Camk2gfl/fl or Atf4fl/fl mice were fed a high-fat, high-calorie diet 
(HFD, 60% kcal from fat) for 13 weeks starting at three weeks of age and were 
maintained on a 12-h light–dark cycle. Fifteen-week-old high-fat-diet-fed obese 
mice (DIO) that had been fed with HFD for nine weeks, four-week old chow-fed 
ob/ob mice, or sixteen-week-old chow-fed wild-type C57BL/6J mice were pur-
chased from Jackson Laboratories and maintained for one week in the animal 
facility before commencement of experiments. Sixteen-week-old DIO Camk2gfl/fl 
mice that had been fed with HFD for 13 weeks were treated with adeno-associated 
viruses (AAV) for expression of either hepatocyte-specific TBG-cre34 or TBG-lacZ 
(the control vector) for three weeks to obtain H-CaMKII(KO) and wild-type mice. 
To obtain ATF4-restored H-CaMKII(KO) or DPP4-restored H-CaMKII(KO) mice, 
TBG-cre-treated Camk2gfl/fl mice received either adeno-Atf4 (H-CaMKII(KO) 
plus adeno-Atf4) or adeno-DPP4 (H-CaMKII(KO) plus adeno-Dpp4), while the 
remaining mice received adeno-lacZ. Similarly, sixteen-week-old Atf4fl/fl DIO mice 
that had been fed with HFD for 13 weeks were treated with AAV8-TBG-cre or 
AAV8-TBG-lacZ to obtain hepatocyte-ATF4 KO (H-ATF4(KO)) and wild-type 
mice. Sixteen-week-old wild-type DIO mice, four-week old ob/ob and sixteen-
week-old wild-type C57BL/6J mice were treated with AAV8–H1-shDpp4 or 
AAV8–H1-control to obtain hepatocyte-specific DPP4 silencing (H-shDpp4) 
or control mice, respectively. In all mouse experiments, recombinant adenovi-
rus (1 × 109 plaque-forming units per mouse) or adeno-associated virus (1 × 1011 
genome copies per mouse) was delivered by tail vein injection, and experiments 
were commenced after 7–28 days or, for the experiment in Extended Data Fig. 
6i, after 11 weeks. DIO mice were treated with oral rivaroxaban (2 mg/kg) twice 
daily for 20 days. DIO mice were treated for four or seven weeks with sitagliptin by 
adding it to the drinking water at 0.3 mg/ml, which results in a dose of ~30–45 mg/
kg/day. Mouse plasma samples were collected from lean or obese mice after 4–5h 
of food withdrawal, with free access to water. Blood glucose was measured after 
4–5h of food withdrawal in mice using a glucose meter (One Touch Ultra, Life-
scan). Plasma insulin levels were measured using the Ultrasensitive Mouse Insulin 
ELISA Kit (Crystal Chem, 90080) and plasma MCP1, IL6 and TNFα levels were 
measured using mouse ELISA kits from RayBiotech (ELM-MCP1-1; ELM-IL6-1; 
ELM-TNFα-1). For gastric inhibitory polypeptide (GIP) and glucagon-like pep-
tide-1 (GLP-1) measurements, mice were fasted overnight and then fed for 4–5 h 
before collecting plasma samples into a tube containing DPP4 inhibitor (5 μM). 
Plasma active GIP was measured using Sandwich mouse active GIP (1–42) ELISA 
Kit (Crystal Chem, 81511) and GLP-1 was assayed in plasma samples using mouse 
active GLP-1 (7–36) ELISA kit (Eagle Biosciences, GP121-K01). Plasma non-esteri-
fied fatty acids (NEFA) were assayed using an enzymatic kit from Wako Diagnostics 
(HR Series NEFA-HR(2)-Colour Reagent A, 999-34691; Solvent A, 995-34791; 
Colour Reagent B, 991-34891; Solvent B, 993-35191; and NEFA standard solution, 
276-76491). Intraperitoneal-glucose tolerance tests were performed by intraperi-
toneal injection of glucose (1 g/kg body weight for DIO, 0.5 g/kg body weight for 
ob/ob and 2 g/kg body weight for lean mice) following an overnight fast. Oral 
glucose tolerance tests were conducted by delivering a 2-g/kg glucose bolus orally 
via gavage to DIO mice after a 5-h fast. Insulin tolerance tests were performed in 
mice that were fasted for 4–5 h, by intraperitoneal insulin injection (0.6 IU/kg body 
weight for DIO, 2 IU/kg body weight for ob/ob and 0.5 IU/kg body weight for lean 
mice) and by assaying blood glucose at various time points. Previous studies and 
pilot experiments formed the basis of power calculations for the various studies. 
Depending on the experiment, calculations indicated that 3–12 mice per group 
would enable the testing of our hypotheses based on an expected 25–30% coef-
ficient of variation and an 80% chance of detecting a 33% difference in the key 
specified endpoints (P < 0.05). For all experiments, male mice of the same age 
and similar weight were randomly assigned to experimental and control groups. 
On occasion, we analysed a subset of mice for a particular parameter, and the 
subset was chosen randomly from a full cohort. Pre-specified exclusion criteria 
were weight loss 10% of initial body weight or signs of illness or injury requiring 
euthanasia. According to these pre-specified criteria, the maximum number of 
mice removed before analysis was three, but was more typically between zero and 
two. Animal studies were conducted in accordance with the Columbia University 
Animal Research Committee. Moreover, because switching mice from group cag-
ing to single caging, improper handling and placing mice in a restrainer affect 
stress-sensitive metabolic parameters including plasma DPP4 levels and adipose 
tissue inflammation (D.S.G., L.O. and I.T., unpublished observations), all experi-
mental mice were housed in groups to avoid stress from isolation and handled with 
extra care to avoid stress during blood glucose measurement and blood collection.
F4/80 immunostaining of VAT. VAT samples were fixed in 10% (v/v) formalin 
solution for 24 h, followed by incubation with 70% ethanol (v/v) for 24 h and then 
embedding in paraffin. Six-micrometre sections were mounted on charged glass 
slides, incubated at 60 °C for 20 min, and deparaffinized using three washes with 
xylene. Antigen retrieval was carried out by treating the sections with proteinase 
K (1:1,000) (Invitrogen, AM2546) at 37 °C for 25 min. The sections were then 
rinsed and blocked using 5% serum, followed by incubation overnight at 4 °C 
with anti-F4/80 biotin-conjugated primary antibody (1:100) (Miltenyi Biotec, 130-
101-893). The sections were then incubated with streptavidin–HRP secondary 
antibody (1:200) (BD Pharmingen, 554066) and then developed in chromagen 
substrate 3,3′-diaminobenzidine (Cell Signaling, 8059) and counterstained with 
haematoxylin. For each mouse, 5–10 sections were analysed by microscopic imag-
ing at 20× magnification. The total number of nuclei and the number of nuclei 
of F4/80-immunostained cells surrounding adipocytes in CLS were counted for 
each field. The data are expressed as mean percentage of CLS macrophages per 
total adipose tissue nuclei.
Portal vein insulin infusion and protein extraction from tissues. After 4–5 h 
of food withdrawal, mice were anaesthetized and insulin (0.6 IU/kg body weight 
for DIO, 2 IU/kg body weight for ob/ob and 0.5 IU/kg body weight for lean mice) 
or PBS was injected through the portal vein. Three minutes after injection, liver 
and adipose tissue were removed, frozen in liquid nitrogen, and kept at −80°C 
until processing. For protein extraction, tissue samples were cut into small pieces 
and transferred to tubes containing ice-cold RIPA buffer supplemented with Halt 
Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific, 78440). Tissue 
segments were then homogenized on ice, lysates were centrifuged, and the super-
natant fractions were used for immunoblot analysis.
Primary hepatocyte experiments. Wild-type C57BL/6J mice (8–10 weeks old) 
were injected with either control vector or AAV8-shDpp4 (H-shDpp4) via tail 
vein injection. Ten days after injection, primary mouse hepatocytes were isolated 
as previously described35. Hepatocytes were incubated with either BSA control or 
palmitate (50 μM) for 10 h, with the last 5 h in serum-free medium. The cells were 
then treated with 100 nM insulin or vehicle control for 5 min and immediately 
frozen in liquid nitrogen and kept at −80 °C until further processing. Cells were 
lysed using 2× Laemmli buffer supplemented with Halt Protease and Phosphatase 
Inhibitor Cocktail and lysates were used for immunoblotting.
Preparation of stromal vascular fraction cells and isolation of adipose tis-
sue macrophages. SVF from lean or obese mice was prepared as previously 
described36. In brief, VAT was isolated in ice-cold PBS containing liberase (50 μg/
ml) and minced into small segments. VAT was digested at 37 °C for 1 h with inter-
mittent mixing. After digestion, the solution was centrifuged, buoyant adipocytes 
were removed, and the cell pellet was retrieved as SVF. SVF cells were then cul-
tured in medium containing 10% (vol/vol) FBS or plasma from lean or obese mice. 
For isolation of ATMs, anti-F4/80 biotin-conjugated primary antibody (Miltenyi 
Biotec, 130-101-893) was added at a 1:10 dilution to 4 × 106 SVF cells in 200 μl of 
PBS containing 5% of FBS (PBS–FBS), followed by incubation at 4 °C for 20 min. 
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The SVF cells were pelleted by centrifugation, washed once with 1 ml of buffer, and 
resuspended in 200 μl of PBS–FBS. The cells were then incubated with streptavi-
din-conjugated magnetic microbeads (1:10) (Miltenyi Biotec, 130-048-101) at 4 °C 
for 20 min. The cells were rinsed once with PBS–FBS, and ATMs were isolated 
using magnetic separation columns (Miltenyi Biotec, 130-042-201) and cultured 
in medium containing 10% (vol/vol) FBS.
Immunoblotting. Proteins from tissue or cell lysates were resolved on 4–20% 
Tris–glycine gradient gels and then transferred to nitrocellulose membranes. The 
membranes were blocked using either 5% non-fat milk or 5% BSA followed by 
incubation with primary antibodies overnight. Blots were then washed thoroughly 
and probed with HRP-conjugated secondary antibodies for 1 h. Protein bands 
were detected with Supersignal West Pico enhanced chemiluminescent solution 
(Thermo Scientific, Cat. No. 34080) and analysed by ImageJ.
Quantitative reverse transcription–PCR. Total RNA was extracted from tissues 
or primary cell cultures using Tri-reagent (Sigma, T9424). cDNA was synthesized 
from 2 μg total RNA using oligo (dT) and Superscript II (Invitrogen, AM5730G 
and 18064014). Real time quantitative (q)PCR was performed with a 7500 Real-
Time PCR System (Applied Biosystems) using SYBR Green master mix (Qiagen, 
204145) and gene-specific primers. The sequences of gene-specific primers used 
for the qPCR assays are described in Supplementary Table 1.
DPP-4 immunodepletion from plasma. DPP-4 was immunodepleted from obese 
mouse plasma using bead-immobilized anti-DPP-4 antibody (R&D Systems, 
AF954) as previously described37. In brief, 10 μg of anti-DPP-4 antibody was con-
jugated with 1.5 mg of Protein-G Dynabeads (Invitrogen, 10004D) in 200 μl of 
binding buffer. After immobilization of anti-DPP4 antibody to beads, 40 μl of DIO 
mouse plasma and 60 μl of PBS were mixed with 40 μl of antibody-coated bead sus-
pension. The resultant mixture was incubated for 2.5 h at 4 °C on a rotating wheel. 
After 2.5 h, Dynabeads were separated with a magnet and discarded. This was 
followed by one more round of immunocapture of DPP4 and discarding of beads. 
DPP-4 proteolytic activity assay was performed on immunodepleted plasma to 
confirm DPP-4 immunodepletion. For some experiments, DIO mouse plasma was 
incubated with anti-DPP4-conjugated or control IgG-conjugated beads, followed 
by elution of the bound material using 50 mM glycine buffer, pH 2.8.
Separation of plasma proteins using FPLC. Lean or obese mouse plasma (0.2 ml) 
was diluted 1:1 with PBS and injected onto a Superdex 200 Increase 10/300GL 
FPLC column (GE Healthcare, 28990944). Plasma proteins were eluted from the 
column at a constant flow of 0.3 ml/min with PBS (pH 7.4). The effluent was col-
lected in 0.25-ml fractions. The collected fractions were frozen in dry ice and kept 
at –80 °C until further processing.
In-gel protein digestion. Inflammatory obese mouse plasma, DPP4-depleted 
obese mouse plasma fractions or DPP4 immunoprecipitated from obese mouse 
plasma (IP-DPP4) were resolved on a 4–20% Tris–glycine gradient gel and then 
stained with GelCode Blue Safe Coomassie stain (Thermo Scientific, 24594) for 
2 h followed by de-staining with double distilled water overnight. The resolved 
proteins were excised and processed at Herbert Irving Comprehensive Cancer 
Center Proteomics Shared Resource, Columbia University. The excised gel pieces 
were rehydrated and digested in 80 μl of 12.5 ng/μl Trypsin Gold in 50 mM ammo-
nium bicarbonate at 37 °C overnight. After digestion was complete, condensed 
evaporated water was collected from the tube walls by brief centrifugation using 
a benchtop microcentrifuge (Eppendorf). The gel pieces and digestion reaction 
were mixed with 50 μL 2.5% trifluoroacetic acid (TFA) and rigorously mixed for 
15 min. The solution with extracted peptides was transferred into a fresh tube. The 
remaining peptides were extracted with 80 μl 70% acetonitrile–5% TFA mixture 
using rigorous mixing for 15 min. The extracts were pooled and dried to comple-
tion (1.5–2 h) in a SpeedVac. The dried peptides were reconstituted in 30 μl 0.1% 
TFA by mixing for 5 min and stored in ice or at −20 °C before analysis.
LC–MS/MS analysis. The concentrated peptide mix was reconstituted in a solution 
containing 2% acetonitrile and 2% formic acid for mass spectrometry analysis. 
Peptides were eluted from the column using a Dionex Ultimate 3000 Nano liquid 
chromatography system with a 10-min gradient from 2% buffer B to 35% buffer B 
(100% acetonitrile, 0.1% formic acid). The gradient was switched from 35% to 85% 
buffer B over 1 min and held constant for 2 min. Finally, the gradient was changed 
from 85% buffer B to 98% buffer A (100% water, 0.1% formic acid) over 1 min, 
and then held constant at 98% buffer A for a further 5 min. The application of a 
2.0-kV distal voltage electrosprayed the eluting peptides directly into the Thermo 
Fusion Tribrid mass spectrometer equipped with an EASY-Spray source (Thermo 
Scientific). Mass spectrometer-scanning functions and HPLC gradients were con-
trolled by the Xcalibur data system (Thermo Finnigan).
Database search and interpretation of MS/MS data. Tandem mass spectra from 
raw files were searched against a mouse protein database using the Proteome 
Discoverer 1.4 software (Thermo Finnigan). The Proteome Discoverer applica-
tion extracts relevant MS/MS spectra from the .raw file and determines the pre-
cursor charge state and the quality of the fragmentation spectrum. The Proteome 
Discoverer probability-based scoring system rates the relevance of the best matches 
found by the SEQUEST algorithm. The mouse protein database was downloaded as 
FASTA-formatted sequences from the Uniprot protein database (database released 
in September, 2014). The peptide mass search tolerance was set to 10 p.p.m. 
A minimum sequence length of seven amino acids residues was required. Only 
fully tryptic peptides were considered. To calculate confidence levels and false 
discovery rates (FDR), Proteome Discoverer generates a decoy database contain-
ing reverse sequences of the non-decoy protein database and performs the search 
against this concatenated database (non-decoy + decoy). Scaffold (Proteome 
Software) was used to visualize searched results. The discriminant score was set 
at less than 1% FDR, determined on the basis of the number of accepted decoy 
database peptides, to generate protein lists for this study. Spectral counts were used 
for estimation of relative protein abundance between samples.
Mouse liver nuclei preparation and chromatin immunoprecipitation assays. 
Mouse liver tissues were homogenized using a Dounce homogenizer (Wheaton) 
with the loose pestle in 1:10 (w:v) of ice-cold NP-40 lysis buffer supplemented with 
protease inhibitor cocktail. Liberation of nuclei was monitored by DAPI staining 
and fluorescence microscopy. To purify intact nuclei, lysates were then layered 
over a sucrose gradient consisting of 1 M sucrose overlaid with 0.68M sucrose 
and then centrifuged at 4000 r.p.m. for 20 min at 4 °C. Following a washing step, 
nuclear pellets were cross-linked with 1% fresh formaldehyde in PBS for 10 min 
at room temperature. Cross-linking was terminated by addition of 200 mM Tris-
HCl (pH 9.4) and 1 mM DTT for 10 min followed by centrifugation at 2,500 r.p.m. 
for 10 min at 4 °C. Nuclear pellets were suspended in SDS lysis buffer containing 
protease inhibitors, incubated for 10 min on ice, and DNA was sheared in a cold 
water bath in a focused-ultrasonicator (Covaris, S2) to obtain DNA fragments with 
an average size of 500 bp. Fragmented chromatin was pre-cleaned by incubating 
with normal rabbit IgG (Santa Cruz, sc-2025) for 1 h at 4 °C, followed by 1 h of 
incubation with 50 μl protein G magnetic beads (Pierce) at 4 °C with rotation. 
A rabbit anti-ATF4 antibody (Cell Signaling, 11815) to pull down ATF4-binding 
complexes, and a control rabbit anti-haemagglutinin antibody (Santa Cruz) were 
used to pull down non-specific binding complexes. Immunoprecipitated chromatin 
fragments were reverse cross-linked, digested by proteinase K, and purified using 
QIAquick PCR Purification Kit (Qiagen, 28104). The presence of ATF4 in the Dpp4 
exonic region was quantified by qPCR and expressed relative to the input genomic 
DNA. The sequences of primers used for the ChIP–qPCR assays are described in 
Supplementary Table 2.
Macrophage assays. ATMs, peritoneal macrophages or BMDMs were incubated 
for 4 h in medium containing 10% plasma from lean or obese mice and then 
assayed for Mcp1 or Il6 mRNA using quantitative reverse transcription–PCR 
(RT–qPCR). ATMs, bone marrow-derived macrophages or human macrophages 
were incubated for 4 h with 0.25 U/ml rFXa, 175 ng/ml rDPP4, or both proteins 
together. The cells were then assayed for Mcp1 or Il6 mRNA using RT–qPCR.
Glucan-encapsulated siRNA particle (GERP) study in ob/ob mice. FITC-labelled 
glucan shells (GS) containing non-targeting (control) siRNA or siRNAs against 
Par2 or Cav1 were prepared and loaded as previously described38,39. In brief, 2.4 mg 
of FITC-labelled glucan shells–lectin, 7.2 nmol of siRNA, and 120 nmol of endo-
porter were combined to form FITC-GERPs. Five-week old ob/ob mice received 12 
daily doses of FITC-GERPs by intraperitoneal injection, which contained 0.2 mg 
FITC-GS, 0.6 nmol siRNA and 10 nmol endoporter. Glucose tolerance and insulin 
tolerance tests were performed on days seven and ten of GERP treatment, respec-
tively. Mice were euthanized 24 h after the last injection.
Statistical analysis. All results are presented as mean ± s.e.m. For experiments 
with two groups, P values were calculated using the two-tailed Student’s t-test 
for normally distributed data and the Mann–Whitney rank sum test for non- 
normally distributed data. For experiments with more than two groups, P values 
were calculated using one-way or two-way ANOVA for normally distributed data 
and the Kruskal–Wallis by ranks test for non-normally distributed data, with 
Student–Newman–Keuls or Dunn’s post hoc test. Error bars that appear to be 
absent from certain graph symbols signify s.e.m. values smaller than the graph 
symbols.
Data availability. The data that support the findings of this study are available 
from the corresponding author upon reasonable request.
32. Lisowski, L. et al. Selection and evaluation of clinically relevant AAV variants in 
a xenograft liver model. Nature 506, 382–386 (2014).
33. Ebert, S. M. et al. Stress-induced skeletal muscle Gadd45a expression 
reprograms myonuclei and causes muscle atrophy. J. Biol. Chem. 287, 
27290–27301 (2012). 
34. Mu, X. et al. Hepatocellular carcinoma originates from hepatocytes and not 
from the progenitor/biliary compartment. J. Clin. Invest. 125, 3891–3903 
(2015).
35. Shimano, H. et al. Overproduction of cholesterol and fatty acids causes 
massive liver enlargement in transgenic mice expressing truncated SREBP-1a. 
J. Clin. Invest. 98, 1575–1584 (1996).
© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
LetterreSeArCH
36. Orr, J. S., Kennedy, A. J. & Hasty, A. H. Isolation of adipose tissue immune cells. 
J. Vis. Exp. 22, e50707 (2013).
37. Nazarian, A. et al. Inhibition of circulating dipeptidyl peptidase 4 activity in 
patients with metastatic prostate cancer. Mol. Cell. Proteomics 13, 3082–3096 
(2014).
38. Aouadi, M. et al. Orally delivered siRNA targeting macrophage  
Map4k4 suppresses systemic inflammation. Nature 458, 1180–1184  
(2009).
39. Cohen, J. L. et al. Peptide- and amine-modified glucan particles for the delivery 
of therapeutic siRNA. Mol. Pharm. 13, 964–978 (2016).
© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
Letter reSeArCH
Extended Data Figure 1 | See next page for caption.
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Extended Data Figure 1 | Hepatocyte-specific deletion of CaMKII or 
ATF4 in DIO mice lowers VAT inflammation. a–c, Sixteen-week-old 
Camk2gfl/fl mice that had been previously fed the DIO diet for 13 weeks 
were injected intravenously with AAV8-TBG-cre (H-CaMKII(KO)) 
or AAV8-TBG-lacZ (wild-type, WT). Mice were analysed after three 
additional weeks on the DIO diet. a, Representative images of VAT 
immunostained for F4/80, with quantification of crown-like-structure 
(CLS) macrophages, and expression of Adgre1 mRNA, which encodes 
F4/80. b, As in a, except that the mice were injected with fluorescent 
beads using a procedure that labels circulating Ly6chi monocytes, and 
then bead-labelled cells were assayed in VAT sections. c, mRNAs for Il6, 
Mcp1, Tnf and Il1b in VAT. d, Blood monocyte count. e, Plasma IL6 and 
TNFα measured by ELISA, and quantification of Adgre1, Mcp1 and Tnfa 
mRNA in liver. In a–e, n = 4 mice per group; mean ± s.e.m.; *P < 0.05; 
n.s., not significant by two-tailed Student’s t-test. f, g, Mice similar to those 
in a–c, and from a third group in which Camk2gfl/fl mice were injected 
intravenously with adeno-Atf4 and AAV8-TBG-cre (H-CaMKII(KO) 
+ adeno-Atf4). f, CLS macrophages and Adgre1 mRNA in VAT were 
quantified, with representative images of F4/80-stained VAT.  g, Il6, Mcp1, 
Tnfa and Il1b mRNA in VAT and Adgre1, Mcp1 and Tnfa mRNA in liver 
were quantified. Note that the first two groups of mice received adeno-lacZ 
instead of adeno-Atf4. n = 4 mice per group; mean ± s.e.m.; *P < 0.05 by 
one-way ANOVA; n.s., not significant. h, AAV8-TBG-cre (H-ATF4(KO)) 
or AAV8-TBG-lacZ (wild-type) was injected intravenously into 16-week-
old Aft4fl/fl mice previously fed the DIO diet for 13 weeks. After three 
further weeks on the DIO diet, VAT from these mice was immunostained 
for F4/80 to identify macrophages, the percentage of macrophages in CLS 
was quantified, and the VAT was assayed for Adgre1 and the indicated 
inflammatory mRNAs. Twelve wild-type and 11 H-ATF4(KO) mice was 
analysed for CLS macrophages, and a randomly selected subset of five 
wild-type and five H-ATF4(KO) mice was analysed for the VAT mRNAs. 
Mean ± s.e.m., *P < 0.05 by two-tailed Student’s t-test.
© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
Letter reSeArCH
Extended Data Figure 2 | DPP4 in the plasma of DIO mice induces 
Mcp1 and Il6 in SVF cells from the VAT of obese mice and in 
macrophages. a, Representative images of haemotoxylin and eosin-stained 
VAT sections from lean and DIO mice and Adgre1 mRNA levels in SVF 
from lean and DIO mice. n = 4 mice per group; mean ± s.e.m.; *P < 0.05. 
b, SVF cells from the VAT of lean mice were incubated for 4 h in medium 
containing 10% (v/v) plasma from lean or DIO mice and then assayed 
for Mcp1 and Il6 mRNA. n = 4 mice per group; mean ± s.e.m.; *P < 0.05; 
n.s., not significant. c, Mcp1 mRNA was assayed in mouse peritoneal 
macrophages (Mφs) or bone marrow-derived macrophages that were 
incubated for 4 h with medium containing 10% (v/v) plasma from  
lean or DIO mice. n = 5 technical replicates per group; mean ± s.e.m.; 
*P < 0.05. d, Mcp1 mRNA levels in SVF cells that were incubated for 
4 h with medium containing 10% (v/v) control or heat-inactivated 
(heat) plasma from the indicated groups of mice. n = 6 mice per group; 
mean ± s.e.m.; *P < 0.05. e, UV protein chromatogram obtained after 
fractionation of DIO mice plasma using gel-filtration FPLC; vertical grey 
bar depicts peak of activity shown in f. f, Obese mouse SVF cells were 
incubated with medium containing 10% lean or DIO mouse plasma or 
the indicated FPLC fractions from e and assayed for Mcp1 mRNA. n.d., 
Mcp1 mRNA not detected. Arrows indicate the fractions that were selected 
for LC–MS/MS analysis. g, LC–MS/MS normalized spectral counts 
corresponding to DPP4 in the FPLC fractions from f. h, DPP4 activity in 
the plasma of lean and DIO mice. n = 5 mice per group; mean ± s.e.m.; 
*P < 0.05. i, SVF cells from DIO mice were incubated for 4 h with medium 
containing 10% (v/v) lean or DIO mouse plasma that was pre-treated for 
1 h with or without 10 μM DPP4 inhibitor KR62436. The cells were then 
assayed for Il6 mRNA. n = 3 technical replicates per group; mean ± s.e.m.; 
*P < 0.05. j, VAT from the mice in Extended Data Fig. 1f, g was assayed 
for Dpp4 mRNA (n = 4). Data in a–c and h were analysed by two-tailed 
Student’s t-test; data in i and j were analysed by one-way ANOVA (g, h); 
data in d were analysed by two-way ANOVA.
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Extended Data Figure 3 | Restoration of DPP4 in livers of 
H-CaMKII(KO) mice abrogates suppression of VAT inflammation 
in DIO mice; ATF4 ChIP of the Dpp4 gene; and AAV8-H1-shDpp4 
treatment lowers hepatic DPP4. Wild-type and H-CaMKII(KO) mice 
and a third group in which Camk2gfl/fl mice were injected intravenously 
with adeno-Dpp4 together with the AAV8-TBG-cre (H-CaMKII(KO) 
+ adeno-Dpp4) were analysed as follows. a, Body weight, plasma DPP4 
activity and liver and VAT DPP4 protein. b, Representative images of 
VAT immunostained with F4/80 antibody, with quantification of CLS 
macrophages and Tnfa and Mcp1 mRNA in VAT. Note that the first two 
groups of mice received adeno-lacZ instead of adeno-DPP4. In a and b, 
n = 3–4 mice per group; mean ± s.e.m.; *P < 0.05 by one-way ANOVA; 
n.s., non-significant. For gel source data, see Supplementary Fig. 1. c, Top, 
ChIP was performed with liver extracts from the indicated groups of 
mice using anti-ATF4 or control IgG antibodies. The region spanning 
the predicted ATF4-binding sequence in exon 1 of Dpp4 was amplified 
by RT–qPCR and normalized to the values obtained from the input. 
n = 3 ChIP assays for wild-type, H-CaMKII(KO), H-CaMKII(KO) + 
adeno-Atf4; n = 1 for H-ATF4(KO); n = 10 for control IgG; mean ± s.e.m.; 
#,*P < 0.05 by one-way ANOVA for groups 1–3. Bottom, per cent input 
for ATF4 ChIP using liver extracts from the indicated DIO mice and 
PCR primers for a region in the Dpp4 gene that does not contain a 
consensus sequence for ATF4 binding. n = 3 ChIP assays for wild type, 
H-CaMKII(KO), H-CaMKII(KO) + adeno-Atf4; n = 1 for H-ATF4(KO); 
n = 10 for control IgG; mean ± s.e.m.; n.s., non-significant by one-way 
ANOVA. d, e, Sixteen-week-old mice previously fed with the DIO diet 
for 10 weeks were injected intravenously with hepatocyte-specific AAV8-
H1-shDpp4 (H-shDpp4) or control AAV8-H1 vector (con). After four 
additional weeks on DIO diet, the mice were analysed as follows. d, DPP4 
immunoblot, with densitometric quantification of DPP4 protein in the 
indicated tissues; representative of three independent experiments. 
e, Dpp4 mRNA in liver and VAT. In d and e, n = 5 mice per group; 
mean ± s.e.m.; *P < 0.05; n.s., non-significant by two-tailed Student’s  
t-test. See Supplementary Fig. 1 for gel source data.
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Extended Data Figure 4 | Silencing of DPP4 in liver suppresses VAT 
inflammation and improves metabolism without increasing plasma 
incretins. a, Top, 16-week-old mice previously fed with the DIO diet 
for 10 weeks were injected intravenously with AAV8-H1-shDpp4 
(H-shDpp4) or control AAV8-H1 vector (con). After four weeks, the 
mice were assayed for Il6, Mcp1, Tnfa and Il1b mRNA in VAT. Bottom, 
control and H-shDpp4-treated mice similar to those above were analysed 
nine days after adenovirus injections for Il6, Mcp1, Tnfa and Il1b mRNA 
in ATMs. b–g, H-shDPP4 and control mice were analysed after four 
weeks. b–d, Representative images of adipose tissue immunostained with 
F4/80 antibody, with quantification of CLS macrophages, Adgre1 and 
inflammatory gene mRNA expression in perirenal, inguinal and brown 
fat. e, Plasma MCP1, IL6 and TNFα. f, Body weight and food intake. 
g, Weights of liver and the indicated adipose tissue depots. In a–g, n = 5–6 
mice per group; mean ± s.e.m.; *P < 0.05; n.s., non-significant by two-
tailed Student’s t-test. h–j, Mice similar to those in b–g were assayed. 
h, Blood glucose and plasma insulin. i, p-AKT and total AKT in VAT 
and liver after insulin injection into the portal vein. n = 1 PBS-injected, 
n = 4 insulin-injected mice per group; blots are representative of three 
independent experiments. Gel source data are shown in Supplementary 
Fig. 1. j, Plasma active GIP (1–42) and GLP1 (7–36). In h and j, n = 6 mice 
per group; mean ± s.e.m.; *P < 0.05; n.s., non-significant by two-tailed 
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Extended Data Figure 5 | Hepatocyte-specific silencing of DPP4 improves 
glucose metabolism in ob/ob mice without increasing plasma incretins 
and does not affect VAT inflammation or glucose metabolism in lean 
mice. a–h, Five-week-old chow-fed ob/ob mice were injected intravenously 
with AAV8-H1-shDpp4 (H-shDpp4) or AAV8-H1-control (con), and were 
assayed four weeks later. a, Body weight. b, Immunoblot of liver and VAT 
DPP4. c, Representative images of VAT immunostained with F4/80 antibody, 
with quantification of CLS macrophages and Adgre1 mRNA in VAT. d, Il6, 
Mcp1, Tnfa and Il1b mRNA in VAT. e, Blood glucose after challenge with 
intraperitoneal glucose or insulin. f, p-AKT and total AKT in VAT and liver 
extracts after portal vein insulin injection. g, Blood glucose and plasma 
insulin 5 h after food withdrawal. h, Plasma active GIP (1–42) and GLP1 
(7–36). i–m, Sixteen-week-old chow-fed wild-type lean mice were injected 
intravenously with AAV8-H1-shDpp4 (H-shDpp4) or AAV8-H1-control 
(Con) and were analysed as follows. i, Body weight. j, Immunoblot of DPP4 
in liver and VAT. k, p-AKT and total AKT in VAT and liver extracts after 
portal vein insulin injection. l, Blood glucose and plasma insulin 5 h after 
food withdrawal. m, Blood glucose after challenge with intraperitoneal 
glucose or insulin. In all panels, n = 5–6 mice per group; mean ± s.e.m.; 
n.s., non-significant by two-tailed Student's t-test. For gel source data, 
see Supplementary Fig. 1.
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Extended Data Figure 6 | Effect of DPP4 silencing on insulin-induced 
p-AKT in primary hepatocytes, on NEFA in obese or lean mice and 
on metabolism in comparison with sitagliptin in obese mice. a, Wild-
type or DPP4-silenced primary hepatocytes were treated with or without 
50 μM palmitate for 10 h with the last 5 h in serum-free medium, and then 
stimulated with 100 nM of insulin for 5 min. p-AKT and total AKT and 
DPP4 were assayed by immunoblot. The data are representative of two 
independent experiments. b, Plasma samples from the following mice were 
assayed for non-esterified fatty acids (NEFA) four weeks after intravenous 
injection with AAV8-H1-shDpp4 (H-shDpp4) or control AAV8-H1 vector 
(con): 16-week-old mice fed the DIO diet for the last 10 weeks, 5-week-
old chow-fed ob/ob mice, and 6-week-old chow-fed wild-type lean mice. 
n = 5–6 mice per group; mean ± s.e.m.; *P < 0.05 and n.s., non-significant 
by two-tailed Student's t-test. c–h, After 10 weeks on high-fat diet, 
control DIO mice, H-shDpp4 DIO mice and DIO mice were administered 
sitagliptin (sita) in drinking water to achieve a dose of ~30–45 mg/kg/
day. After 4 weeks of treatment, the mice were analysed as follows. c, Body 
weight. d, Plasma and VAT DPP4 activity. e, Hepatic DPP4 immunoblot 
and hepatocyte DPP4 activity. f, Blood glucose and plasma insulin 5 h after 
food withdrawal. g, p-AKT and total AKT in VAT and liver after portal 
vein insulin injection. h, Plasma non-esterified fatty acids (NEFA). For all 
quantified data panels except e, n = 6–8 mice per group; for e, n = 4 mice 
per group; mean ± s.e.m.; *,#P < 0.05 and n.s., non-significant by one-way 
ANOVA. For gel source data, see Supplementary Fig. 1. i, DIO mice were 
treated with AAV8-H1-con, AAV8-H1-shDpp4 or sitagliptin (+ AAV8-
H1-con) exactly as above, except the mice were analysed after 11 weeks of 
treatment instead of after 4 weeks. n = 5 mice per group; mean ± s.e.m.; *,# 
P < 0.05 and n.s., non-significant by one-way ANOVA.
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Extended Data Figure 7 | DPP4 requires a plasma factor to induce 
inflammation in SVF. a, Mcp1 mRNA was assayed in SVF cells that 
were incubated for 4 h with medium containing 10% (v/v) DIO mouse 
plasma; DIO mouse plasma immunodepleted of DPP4; recombinant 
DPP4 (rDPP4) alone; or rDPP4 plus DIO mouse plasma immunodepleted 
of DPP4. n = 3 technical replicates per group;. mean ± s.e.m. b, As a, 
except plasma from H-shDPP4 DIO mice were used instead of DPP4-
depleted obese mouse plasma, and both Mcp1 and Il6 were assayed (n = 5 
technical replicates per group; mean ± s.e.m.). In a and b, groups with 
different symbols are different from each other (P < 0.05 by one-way 
ANOVA). c, DPP4-depleted plasma from DIO mice was fractionated by 
Superdex-200 FPLC. Each fraction, as well as unfractionated DIO mouse 
plasma, was incubated with SVF cells with or without rDPP4, followed 
by assay of Mcp1 mRNA. n.d., Mcp1 mRNA not detected. The fraction 
numbers in red (arrows) were selected for LC–MS/MS analysis. The data 
are from a single experiment.
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Extended Data Figure 8 | DPP4 and FXa synergistically promote  
VAT inflammation, and inhibition of FXa improves glucose  
metabolism. a, LC–MS/MS normalized spectral counts corresponding  
to FX in the indicated FPLC fractions from Extended Fig. 7c. b, SVF  
cells or BMDMs were pre-incubated for 1 h with or without 10 μM FXa  
inhibitor rivaroxaban (riv) and then incubated with medium containing  
10% (v/v) plasma from lean or DIO mice and assayed for Mcp1 mRNA.  
n = 3 technical replicates per group; mean ± s.e.m.; *,#P < 0.05 by two- 
way ANOVA. c, BMDMs were pretreated with or without 10 μM FXa  
inhibitor rivaroxaban (riv) or 10 μM DPP4 inhibitor KR62436, followed by  
incubation for 4 h with rFX or rDPP4 alone or both together. Il6 mRNA 
was then quantified. n = 4 technical replicates per group; mean ± s.e.m.; 
#,*P < 0.05 by one-way ANOVA. d, SVF cells from lean or DIO mice were 
treated with rFX or rDPP4 alone or in combination for 4 h, and then Mcp1 
and Il6 mRNA levels were assayed (n = 4 technical replicates per group; 
mean ± s.e.m.; *P < 0.05 and n.s., non-significant by one-way ANOVA).  
e–j, The control and rivaroxaban-treated mice from Fig. 3b, c were  
assayed. e, Body weight. f, Adgre1, Mcp1, Il6, Tnfa and Il1b mRNA in VAT.  
g, h, Blood glucose and plasma insulin 5 h after food withdrawal. i, p-AKT  
and total AKT in VAT and liver after portal vein insulin injection. j, Plasma  
non-esterified fatty acids (NEFA). In e–h and j, n = 5 mice per group; 
mean ± s.e.m.; *P < 0.05 and n.s., non-significant by two-tailed Student’s 
t-test. In i, the mean fold increases of the plus-insulin values relative to 
the minus-insulin value, based on the densitometric ratio of p-AKT:total 
AKT, are shown below the blots (n = 1 PBS-injected and n = 4-insulin 
injected mice per group; mean ± s.e.m.; *P < 0.05). For gel source data, see 
Supplementary Fig. 1.
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Extended Data Figure 9 | See next page for caption.
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Extended Data Figure 9 | DPP4 and FXa synergistically induce 
inflammatory signalling pathways in macrophages. a, BMDMs were pre-
treated for 4 h with or without 0.25 U rFXa, medium was then removed, 
cells were washed and treated with 10 μM rivaroxaban (riv) to inhibit 
residual FXa activity. The cells were then incubated for 4 h with or without 
70 ng rDPP4 and assayed for Mcp1 and Il6 mRNA. b, BMDMs were pre-
treated for 4 h with or without 70 ng rDPP4, medium was then removed, 
cells were washed and treated with 10 μM KR62436 to inhibit residual 
DPP4 activity. The cells were then incubated for 4 h with or without 0.25 U 
rFXa and assayed for Mcp1 and Il6 mRNA. In a and b, n = 3 technical 
replicates per group; mean ± s.e.m.; *P < 0.05 versus all other groups by 
one-way ANOVA. c, ATMs were pre-treated for 1 h with or without 10 μM 
of the PAR2 inhibitor GB83, 25 μM of the CAV1 inhibitor daidzein, 10 μM 
of the MEK inhibitor PD98059 or 10 μM of the IKK inhibitor PS-1145. 
The cells were then incubated for 4 h with or without rFXa and rDPP4 
and assayed for Mcp1 and Il6 mRNA. n = 4 technical replicates per group; 
mean ± s.e.m.; *,#P < 0.05 by one-way ANOVA. d, Human monocyte-
derived macrophages were pre-treated for 1 h with or without 10 μM PAR2 
inhibitor (GB83) or 25 μM CAV1 inhibitor (daidzein) and then  
incubated for 4 h with or without rFXa, rDPP4 or both and assayed 
for MCP1 and IL6 mRNA. n = 3 technical replicates; mean ± s.e.m.; 
#,*P < 0.05 versus all other groups by one-way ANOVA. e–g, Bone 
marrow-derived macrophages were incubated for 10 min with or 
without 0.25 U rFXa, 70 ng rDPP4 or rFXa plus rDPP4 and then assayed 
by immunoblot for phosphorylated and total IRAK1, TAK1, RAF1, 
ERK1/2 and P65, followed by densitometric quantification. The data are 
representative of two (e, f) or three (g) independent experiments. For 
all panels, n = 3 technical replicates per group; mean ± s.e.m.; *P < 0.05 
versus other groups and n.s., not significant by one-way ANOVA. 
h–j, Bone marrow-derived macrophages were pretreated for 1 h with or 
without the following inhibitors. h, IRAK-1/4 inhibitor-I, 0.5 μM. i, TAK1 
MAPKKK inhibitor Z-7-oxozeaenol, 0.1 μM. j, RAF1 inhibitor GW5074, 
1 μM. Cells were then incubated for 4 h with or without rFXa plus rDPP4 
and assayed for Mcp1 and Il6 mRNA. n = 4 technical replicates per group; 
mean ± s.e.m.; *P < 0.05 by one-way ANOVA.
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Extended Data Figure 10 | Supporting data for GERP experiments. 
a, Five-week-old chow-fed ob/ob mice were treated daily by intraperitoneal 
injection of FITC-labelled glucan shells for 12 days and then assayed by 
DAPI staining, F4/80 immunofluorescence and glucan shell fluorescence 
in the indicated tissues. b–e, Five-week-old chow-fed ob/ob mice were 
injected intraperitoneally once daily for 12 days with 0.2 mg GERPs 
containing scrambled siRNA (control), Par2 siRNA or Cav1 siRNA. 
The mice were analysed 24 h after the last injection. b, Body weight. 
c, Immunoblots of PAR2 and CAV1 in ATMs and splenic extracts. d, Il6, 
Mcp1, Tnfa and Il1b mRNA in VAT. e, Plasma non-esterified fatty acids 
(NEFA). In b, d and e, n = 5–6 mice per group; *P < 0.05 and n.s., non-
significant by two-tailed Student’s t-test for each siRNA GERP versus 
control GERP. For gel source data, see Supplementary Fig. 1.
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?    Experimental design
1.   Sample size
Describe how sample size was determined. Previous studies and pilot experiments form the basis of power calculations for the various 
studies. Depending on the experiment, calculations indicated that 3-12 mice per group would 
enable the testing of our hypotheses based on an expected 25-30% coefficient of variation 
and an 80% chance of detecting a 33% difference in the key specified endpoints ( P =0.05)
2.   Data exclusions
Describe any data exclusions. Pre-specified exclusion criteria were weight loss>10% of initial body weight or signs of illness 
or injury requiring euthanasia. According to these pre-specified criteria, the maximum 
number of mice removed before analysis was 3, but more typically 0-2.
3.   Replication
Describe the measures taken to verify the reproducibility 
of the experimental findings.
All experiments were reproducible as assessed in multiple wells of cells, tissue samples or 
mice. We did not have cases of irreproducibility. Please note that the bar graphs depicting 
spectral counts (Ext. Data Fig. 2g and Ext. Data Fig. 8a) simply represent a single MS/MS 
experiment, and likewise the FPLC fractions (Ext. Data Fig. 2f and Ext. Data Fig. 7c) were 
screened using technical duplicates, but all of these data were subjected to extensive 
reproducibility in all the subsequent biological assays related to these data.
4.   Randomization
Describe how samples/organisms/participants were 
allocated into experimental groups.
Mice of the same age and similar weight were randomly assigned to experimental and 
control groups. On occasion, we analyzed a subset of mice for a particular parameter, and the 
subset was chosen randomly from a full cohort. 
5.   Blinding
Describe whether the investigators were blinded to 
group allocation during data collection and/or analysis.
The investigators were not blinded during cell and mouse experiment assays.
Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.






6.   Statistical parameters 
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the 
Methods section if additional space is needed). 
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same 
sample was measured repeatedly
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
Test values indicating whether an effect is present 
Provide confidence intervals or give results of significance tests (e.g. P values) as exact values whenever appropriate and with effect sizes noted.
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
?   Software
Policy information about availability of computer code
7. Software
Describe the software used to analyze the data in this 
study. 
Image J for density ratio measurements;  Proteome Discoverer 1.4
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made 
available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for 
providing algorithms and software for publication provides further information on this topic.
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Policy information about availability of materials
8.   Materials availability
Indicate whether there are restrictions on availability of 
unique materials or if these materials are only available 
for distribution by a third party.
No restrictions--all mutant mice are commercially available or available from the labs 
indicated in the manuscript, and the methods for GeRP construction is published.
9.   Antibodies
Describe the antibodies used and how they were validated 
for use in the system under study (i.e. assay and species).
The source and catalogue number of all antibodies appear in Methods. Antibodies were 
validated by showing lack of signal after knockout or siRNA or by a single major band at the 
proper MW on immunoblot.
10. Eukaryotic cell lines
a.  State the source of each eukaryotic cell line used. N/A
b.  Describe the method of cell line authentication used. N/A
c.  Report whether the cell lines were tested for 
mycoplasma contamination.
N/A
d.  If any of the cell lines used are listed in the database 
of commonly misidentified cell lines maintained by 
ICLAC, provide a scientific rationale for their use.
N/A
?    Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
11. Description of research animals
Provide all relevant details on animals and/or 
animal-derived materials used in the study.
All details appear under "Mouse experiments" section in methods






Policy information about studies involving human research participants
12. Description of human research participants
Describe the covariate-relevant population 
characteristics of the human research participants.
N/A
